白蛋白结合型紫杉醇治疗胃癌的研究进展

Research Progress of Albumin-Bound Paclitaxel for Gastric Cancer

胃癌在我国的发病率和死亡率均较高,手术、放疗和化疗为胃癌的标准治疗方法,尽管取得了明显的临床获益,但胃癌的总体预后仍很差。化疗可以在一定程度上延缓肿瘤的进展,延长患者的生存时间,纳米粒白蛋白紫杉醇是由白蛋白与紫杉醇结合形成,主要通过抑制细胞分裂,从而达到杀灭肿瘤细胞的目的,具有抗肿瘤效果好、给药方便、药物副作用低等优点,因此近年来关于白蛋白结合紫杉醇在胃癌治疗中的应用,广泛开展了基础和临床研究。本文就白蛋白结合型紫杉醇在胃癌治疗中的研究进展进行综述。

Gastric cancer has a high morbidity and mortality rate in China, and surgery, radiotherapy and chemotherapy are the standard treatments for gastric cancer;despite the obvious clinical benefits achieved, the overall prognosis of gastric cancer is still poor. Chemotherapy can delay the pro-gression of tumor and prolong the survival time of patients to a certain extent, and nanoparticle albumin paclitaxel is formed by combining albumin and paclitaxel, mainly by inhibiting cell divi-sion, thus achieving the purpose of killing tumor cells, which has the advantages of good anti-tumor effect, convenient administration and low drug side effects, therefore, in recent years, the application of albumin combined with paclitaxel in the treatment of gastric cancer has been widely carried out. In this paper, we have discussed the application of albumin-conjugated paclitaxel in the treatment of gastric cancer. In this paper, we review the research progress of albumin-bound paclitaxel in the treatment of gastric cancer.